Effect of Raisins on Cognitive Function in Healthy Older Adults

Status Completed

Clinical Trial Summary

Objective:To assess the effect of an intervention based on including 50 g of raisins (sultanas) daily in the diet for 3 months on improving cognitive performance, cardiovascular risk factors and inflammatory markers in a population of older adults without cognitive impairment. Methodology: Randomised two parallel-group clinical trial. Population: 80 patients between 70 and 80 years of age will be included, selected from primary care clinics in Salamanca and Zamora. Measurements and intervention: Participants included in the study will have a baseline visit and two evaluations visits at 3 and 6 months where cognitive performance (attention, executive functions, verbal memory, working memory and language) will be assessed using a brief neuropsychological battery; quality of life, using the WHOQol- AGE and EUROQOL-5D questionnaire; blood pressure; glycaemia; body composition, using an impedancemeter; and different markers of inflammation, interleukin (IL) 6, IL-1 and tumour necrosis factor alpha (TNF); and different markers of inflammation, interleukin (IL) 6, IL-1 and tumour necrosis factor alpha (TNF-α). Participants will be randomised using the Epidat 4.0 programme into 2 groups (control group and intervention group) with a ratio of 1:1. Both groups will be instructed to continue with their usual dietary pattern without changing their habits during the study period. Those in the control group will not receive any amount of raisins to their usual diet. The participants in the intervention group will receive 50 g of raisins and instructions on the time of day to take it (at night). The duration of this intervention will be 3 months. The daily nutritional intake of this amount of raisins is as follows: 146 kcal; 0.25 g of fat; 34 g carbohydrates of which 34 g sugars; 1.3 g protein; 1 g fibre. The total polyphenol content of total polyphenols from 50 g of raisinas is approximately 532,5 mg (phenols explorer database).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cognitive Dysfunction

Clinical Trial Details

NCT number	NCT04966455
Study type	Interventional
Source	University of Salamanca
Contact
Status	Completed
Phase	Phase 3
Start date	September 20, 2021
Completion date	May 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05273125` - MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
Active, not recruiting	`NCT04049695` - Improving Cognition After Cancer	N/A
Completed	`NCT05912374` - Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs	N/A
Recruiting	`NCT03977350` - Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
Not yet recruiting	`NCT06027632` - Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer	N/A
Terminated	`NCT00754052` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17	Phase 3
Completed	`NCT00719628` - Depth of Anaesthesia and Cognitive Dysfunction	N/A
Terminated	`NCT00754013` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10	Phase 3
Recruiting	`NCT05014399` - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting	`NCT05372159` - Vanderbilt Memory and Aging Project
Completed	`NCT03243279` - BRS and Outcomes in Cardiothoracic Surgery
Completed	`NCT04093882` - The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease
Recruiting	`NCT05732285` - A Pilot Randomized Controlled Trial: CoINTEGRATE	N/A
Completed	`NCT06059768` - Urdu Translation and Psychometric Analysis of Lawton IADLS.
Completed	`NCT04562662` - Evaluation of mediVR-KAGURA Guided Therapy	N/A
Completed	`NCT04624529` - Validity and Reliability of a Self-evaluation Tool for Cognitive Deficits in the Acute Stage After Stroke
Not yet recruiting	`NCT04079075` - Multiple Interventions to Prevent Cognitive Decline	N/A
Active, not recruiting	`NCT04638101` - Building the Path to Resilience in Preterm Infants: Mindfulness-based Intervention	N/A
Active, not recruiting	`NCT04556305` - Lifestyle Physical Activity and Cognitive Training Interventions	N/A
Completed	`NCT03933475` - Telerehabilitation for Cognitive Impairment Following Acquired Brain Injury	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.